Hematology/Oncology

Top Story

Rutgers Cancer Institute appoints co-program leader

Rutgers Cancer Institute appoints co-program leader
June 26, 2016

Stephen K. Burley, MD, DPhil, has been named co-program leader of the cancer pharmacology research program at Rutgers Cancer Institute of New Jersey.

Burley is director of the Center for Integrative Proteomics Research, founding director of the Institute of Quantitative Biomedicine, director of the Research Collaboratory for Structural Bioinformatics Protein Data Bank, and a professor of chemistry and chemical biology at Rutgers University.

Wistar Institute executive receives professorship

June 25, 2016
David B. Weiner, PhD, executive vice president of The Wistar Institute and director of The Wistar Institute Vaccine Center, has received the W.W. Smith Charitable Trust…
Editorial

Cancer and the world economy (Please read this, Vice President Biden!)

HemOnc Today, June 25, 2016
Derek Raghavan, MD, PhD
I was interested to see a report in TheLancet noting that there was a significant spike in cancer deaths associated with the financial crash from 2008 to 2010. On a…
Imaging Analysis

A 45-year-old woman with pulmonary venous metastasis from uterine leiomyosarcoma

HemOnc Today, June 25, 2016
Ajit Karambelkar, MD; Munir Ghesani, MD, FACNM
A 45-year-old woman reported she had experienced bloating and felt lower abdominal pressure for the past 3 months. Ultrasound showed a large uterine fibroid. Further…
Commentary

The denominator problem in clinical oncology

HemOnc Today, June 25, 2016
William Wood, MD
I have a fairly typical academic oncology practice. As a bone marrow transplant physician, I primarily see patients who have acute or chronic leukemia, lymphoma or…
More News Headlines »
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Video
Meeting News Coverage

VIDEO: CPX-351 improves outcomes for elderly patients with high-risk AML

June 20, 2016
More »
Featured
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

CME

Updates from Vienna 2015 – Highlights in Hematologic Malignancies

This activity is supported by an educational grant from Genentech, Inc.

The management of patients with hematologic malignancies—from diagnosis to treatment decisions—can represent a…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan